Conclusion
STAT1 gene defect should be considered in recurrent fungal infections.
After the diagnosis, the phosphorylation study must be done in terms of
treatment. HSCT should be considered before complications develop at the
time of diagnosis. When HSCT cannot be applied, ruxolutinib can be
administered to control autoimmune findings lung findings and
candidiasis.